Review Article

Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Update for Clinicians

Table 2

Pharmacologic profiles of new oral anticoagulants in clinical use.

DabigatranRivaroxabanApixabanEdoxaban

TargetThrombinFactor XaXaXa
AdministrationOnce or twice dailyOnce dailyTwice dailyOnce daily
ProdrugYesNoNoNo
Half-life (hours)12–175–98–159–11
(hours)0.5–22–43-41-2
Bioavailability3–7%66–100% 50% 50%
Protein binding35%92–95%87%40–59%
Renal excretion80%33%27%35%

: time to peak.